


Supporting life when bio is failing

# CYBERNETICS NOW




#### **Artificial Organs**

Artificial heart can last years




#### **Brain Computer Interfaces**

Paralized man walked



#### **Ex Vivo Organ Perfusion**

Human lung kept ex vivo for hours




### CYBERNETICS FUTURE



# Cyborgization will provide an alternative path to radical lifespan extension, outpacing drugs

- > Organs are already kept alive on machines for days
- > Isolating the head on a perfusion system could prevent 90% of mortality causes effectively bypassing organ failure
- > This alone could extend average human lifespan by a decade





### HEAD PERFUSION: HISTORICAL CONTEXT



First experiments in keeping the alive head on the blood circulation system was done in USSR 1928 by Sergei Brukhonenko

- > Mechanical blood pump (early heart-lung machine prototype)
- > Manual lung ventilation (bellows)
- > Circulating autologous blood



3.5 hours





#### HEAD/BRAIN PERFUSION: TODAY



- > Several academic studies demonstrated brain perfusion
- > At least 2 commercial companies researching brain perfusion
- > No one has attempted **live** head perfuion since 1928!

# nature

Article Published: 17 April 2019

# Restoration of brain circulation and cellular functions hours post-mortem

Zvonimir Vrselja, Stefano G. Daniele, John Silbereis, Francesca Talpo, Yury M. Morozov, André M. M. Sousa, Brian S. Tanaka, Mario Skarica, Mihovil Pletikos, Navjot Kaur, Zhen W. Zhuang, Zhao Liu, Rafeed Alkawadri, Albert J. Sinusas, Stephen R. Latham, Stephen G. Waxman & Nenad Sestan 

✓

Nature 568, 336–343 (2019) Cite this article



#### Chinese Journal of Traumatology

Available online 22 December 2024

In Press, Corrected Proof ② What's this?




Original Article

Protective effect of sub-hypothermic mechanical perfusion combined with membrane lung oxygenation on a yorkshire model of brain injury after traumatic blood loss

Xiang-Yu Song <sup>a 1</sup>, Yang-Hui Dong <sup>b 1</sup>, Zhi-Bo Jia <sup>c 1</sup>, Lei-Jia Chen <sup>b c</sup>, Meng-Yi Cui <sup>c</sup>,

Yan-Jun Guan <sup>c d</sup>, Bo-Yao Yang <sup>c d</sup>, Si-Ce Wang <sup>c d</sup>, Sheng-Feng Chen <sup>e</sup>, Peng-Kai Li <sup>c d</sup>, Heng Chen <sup>c</sup>

Hao-Chen Zuo <sup>c</sup>, Zhan-Cheng Yang <sup>c</sup>, Wen-Jing Xu <sup>e 2</sup>, Ya-Qun Zhao <sup>f 2</sup>, In Indian Peng <sup>c 2</sup>



## LONG-TERM SCALABLE HEAD PERFUSION



Done

Someone is doing

Our todo

Nutrients

**Buffers** 

Hormonal signaling factors

**Metabolic factors** 

**Oxygen Carriers** 

**Immune system componnts** 

**Coagulation agents** 

**✓** HeartLung function

Kidney function

**Liver detox function** 


Blood substitute/ bioproduction

Homeostasis device

Sensor-guided feedback control

Real-time monitoring

**Spinal Cord Termination Interface** 




#### LIVER PERFUSION AS ENTRYPOINT



#### 4 reasons to start with liver:

- 1. Head survival is gated by liver viability
- 2. Technical stepping stone to head perfusion
- 3. No artificial liver exists currently
- **4.** Discarded livers = scalable testing platform for the entire device
- **5.** Liver perfusion market growing at 18% CAGR a sustainable commercial path while developing the full solution



# Liver protects neuron viability and electrocortical activity in post-cardiac arrest brain injury

 $\nearrow$ 

Brain injury is the leading cause of death after cardiac arrest, and liver dysfunction worsens neurological outcomes. Experimental models show that liver function directly influences brain injury, recovery, and neural activity.



### LIVE ORGAN PRESERVATION MARKET




100k on transplant list, 17 deaths / day

50k transplants in the US in 2024



OrganOX - 24 hours



1 extra day of liver perfusion could save 10,000 lives / year (chatGPT 40)







ANDREI PANFEROV

Chief Executive Officer

Serial Tech Entrepreneur.

TalentRiver - HRTech AI, Stockholm, hit breakeven, raised seed, scaling now.

Dowell Bio - Made breakthrough in spinal cord fusion (a century problem, preparing clinical trials for 2025).





**TOMER LANDSBERGER**Chief Scientific Officer

Scientist and entrepreneur.

PhD Computational Immunology from Weizmann Institute of Sceince, MSc Theoretical Physics, MA Philosophy.

Founder of Day8. Desci researcher. Ex VitaDAO, Gero, Michael Levin lab. Science communicator.

WEIZMANN INSTITUTE OF SCIENCE



MICHELE DIANA, MD
Chief Medical Officer

MedTech entrepreneur.

Chief Innovation Officer of Department of Surgery of the University Hospital of Geneva.

Founder & CMO of Astranice.

Professor at University of Strasbourg and University of Geneva.





**ALEXEY TOPTUN**Chief Technical Officer

Lead Design engineer.

Previously worked with submarine engines, high-precision lasers, robotics, chemical production and electronics.

Experienced in full cycle from concepts to mass production and maintenance in point-of-use.





**ERIC FELLI**Expert in Hepatology

Performed the first recellularization of an entire human liver.


PhD thesis in assessment of liver viability using hyper-spectral imaging, deep-learning driven organs valuation.



#### OUR STUDIES




#### Incorporating real-time assesment of organ quality during perfusion



#### Hyperspectral Viability Scoring

Deep-learning analysis of HSI images predicts graft viability during perfusion—enables objective, real-time assessment of organ quality






#### **HSI Oxygenation Mapping**

Real-time, non-invasive quantification of liver oxygenation distinguishes ischemia types—guides optimization of perfusion parameters

scientific reports



#### **Porcine IRI Model Protocol**

Standardized pig liver ischemia/reperfusion protocol—provides reproducible platform to test and refine ex vivo perfusion strategies



### ORGAN PRESERVATION MACHINE



Real-time organ and blood monitoring & infusions

Long-term safer oxygenation

Pulsatile heart-lung machine



Organ massage

Sterilization in ambient air, featuring full contour-following temperature management

50% smaller footprint

# COMPETATIVE ANALYSIS



	OrganOx Metra	TransMedics OCS Liver	Sciborg ExMachina	
Temperature Control	± 0.5 °C	± 0.5 °C	± 0.1 °C	
Blood traumatisation	<b>High</b> membrane, roller pump	<b>Medium</b> membrane, pilsatile pump	<b>Lower</b> no membrane, pulsatile pump	
Oxygen source	Cylinder	Cylinder	Sterilized atmospheric air	
Feedback loops	Limited by usual monitoring	Limited by usual monitoring	Celluar-level monitoring, AI feedback loop	
Sterility	Lack of sterility control	Lack of sterility control	Self-cleaning Space-tech grade sterility	
Mechanical stimulation	None	None	Organ massage & lymph drainage	
Consumables cost	£7 210	\$40 000 £2 500		
Viable Preservation Duration Up to 24 h		Up to 24 h 72+h		

### OUR FUTURE APPLICATIONS

We need to reshape to all these devices. They are outdated.

# **Blood purification** & infusions

Apheresis, infusion pumps, renal therapy, precision infusion

\$ 3.9 bln by 2030



# Blood circulation & oxygenation

ECMO, Heart-Lung, Autotransfusion

\$ 5 bln by 2030



# Organs preservation & restoration

Heart, liver, kidney, lung, bone marrow

\$ 9 bln by 2030







	2024	2025		2026-2027	2028
Legal		Opening AG in Switzerland	Filing IP with the University of Geneva	Support by InnoSwiss - 550 000 CHF	VC Raise
Tech	Platform asse	mbly		Pre-clinical iterations	Cinical trials with liver preservation

- > Right now, we're close to prototyping the initial platform, which is required for iterating on the whole blood perfusion cycle at the same time
- > We're looking for a bridge support to prepare the legal infrastructure in Switzerland
- > After we formulate a company, we'll file IP and get support from the Swiss scientific infrastructure for 2 yrs of pre-clinical iterations in University of Geneva's Hospital





#### **OPEN ROUND**

€ 200.000 at valuation of € 5.000.000 in Sciborg AG (Switzerland)

#### **MINIMAL TICKET**

€20.000

#### **EXPECTED GROWTH**

**4x in 2 yrs**, after we pass scientific research incubation at the University of Geneva and raise the first VC round for clinical trials



#### CONTACT US

Let's build critical care, that the world deserves

t.me/andreypnfrv
linkedin.com/in/andreypnfrv
andrei@sciborg.xyz

Book a call: <u>calendar.app.google/RYR9DpPpcUZWCpc96</u>

